drugset / Trial / NCT04057365
Study of the Combination of DKN-01 and Nivolumab in Previously Treated Patients With Advanced Biliary Tract Cancer (BTC)
Phase 2
Terminated
15 enrolled
Massachusetts General Hospital
Bristol-Myers Squibb · collabLeap Therapeutics, Inc. · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This research is studying the effect of the combination of how two study drugs (Nivolumab and DKN-01) works in people with advanced biliary tract cancer.
Timeline
- Start
- 2019-10-07
- Primary completion
- 2022-09-25
- Completion
- 2022-09-25
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | DKN-01 | Monoclonal antibody | — | Intravenous |
| Subject | Nivolumab | Monoclonal antibody | — | Intravenous |